血清癌胚抗原对接受立体定向体部放疗的非小细胞肺癌患者的预后意义
Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy.
作者信息
Shintani Takashi, Matsuo Yukinori, Iizuka Yusuke, Mitsuyoshi Takamasa, Mizowaki Takashi, Hiraoka Masahiro
机构信息
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
出版信息
Anticancer Res. 2017 Sep;37(9):5161-5167. doi: 10.21873/anticanres.11937.
BACKGROUND/AIM: To examine the prognostic significance of serum carcinoembryonic antigen (CEA) for stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT).
PATIENTS AND METHODS
In total, 129 stage I NSCLC patients were analyzed and divided into two groups: CEA-High (CEA>5 ng/ml) and CEA-Low (CEA≤5 ng/ml).
RESULTS
Median follow-up time was 38 months. Overall survival was not significantly different between CEA-High (n=47) and CEA-Low (n=82) patients (57% vs. 63% at 3 years; p=0.39), although progression-free survival (PFS) was significantly worse in CEA-High patients (31% vs. 51% at 3 years; p=0.01). Larger tumor size and high CEA level were independent prognostic factors for worse PFS. Failure pattern analysis showed that regional node or distant recurrence was more common in CEA-High patients (47%) than in CEA-Low patients (29%).
CONCLUSION
Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully.
背景/目的：探讨血清癌胚抗原（CEA）对接受立体定向体部放疗（SBRT）的Ⅰ期非小细胞肺癌（NSCLC）患者的预后意义。
患者与方法
共分析129例Ⅰ期NSCLC患者，分为两组：CEA高组（CEA>5 ng/ml）和CEA低组（CEA≤5 ng/ml）。
结果
中位随访时间为38个月。CEA高组（n = 47）和CEA低组（n = 82）患者的总生存期无显著差异（3年时分别为57%和63%；p = 0.39），尽管CEA高组患者的无进展生存期（PFS）显著更差（3年时分别为31%和51%；p = 0.01）。肿瘤体积较大和CEA水平较高是PFS较差的独立预后因素。失败模式分析显示，CEA高组患者（47%）区域淋巴结或远处复发比CEA低组患者（29%）更常见。
结论
CEA高的Ⅰ期NSCLC患者区域或全身复发风险较高，应密切随访。
Zotero 插件